• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
    • РусскийРусский
  • Menu

How to increase patient and health care provider awareness of diseases? Russian experience.

21.07.2021/in Publications /by Marketing

In Russia and the CIS, problems of lack of disease awareness, as well as gaps in understanding of patient pathways and local treatment regimens, have been identified.

Because of this, there is now an active initiative to collect these data from patients with classical Hodgkin lymphoma (cHL), systemic anaplastic large cell lymphoma (sALCL), and inflammatory bowel disease (IBD).

These issues were also discussed at the 8th Conference of the International Society for EBHC.  Representatives of Takeda Pharmaceuticals, 3K-Research LLC Moscow, X7 Research, Statandocs, discussed how to increase disease awareness and improve patient care.

Conference participants: Maria Leer, Tatiana Goldina, Nikolai Suvorov, Ekaterina Maslak, Kanyshay Mamyrbaeva, Artem Igoshin, Kira Efimochkina, Vitaly Marchuk, Evgenia Osipova, Svetlana Tolstova, Valentina Koyavo, Dmitry Koloda, Olga Fadeeva, Irina Murashko, Andrey Bazovoy, Sergey Simeniv, Nikolai Chertishchev, Dmitry Kryuchkov, Alexander Solodovnikov.

One of the proposed solutions to the problems: using registries to demonstrate actual data from patients with Hodgkin’s lymphoma, systemic anaplastic large cell lymphoma, and IBD, and how this data can raise awareness of the disease and support improved patient outcomes in Russia and the CIS.

For example, INTENT is a unique and most comprehensive registry of IBD, covering Russia, Belarus, and Kazakhstan. This registry plans to include up to 3,000 patients with IBD (ulcerative colitis [UC] and Crohn’s disease [CD]), recording at least 2 years of medical history at the time of patient inclusion; patients will be followed for at least one year. There is also “KLIO,” the largest national multicenter disease registry in Russia, aimed at improving outcomes in adult patients with Hodgkin lymphoma and systemic (either newly diagnosed or confirmed Hodgkin lymphoma, or patients with relapsing-remitting Hodgkin lymphoma or sALCL). The registry aims to enroll 3,000 patients and record a 3-year history before inclusion.

How can these registries help in practice?

The data from the registries will help inform health care professionals and patients about the current disease situation, treatment costs, and challenges associated with diagnosing and treating disease, with the development of initiatives that will help more accurately diagnose disease and provide timely treatment. Through dissemination of results (e.g., through publications, educational seminars), it is anticipated that greater awareness of these diseases, including subpopulations, patient movements, and areas of high unmet need, will be possible in Russia and the CIS. The creation of disease registries will facilitate greater collaboration among health care providers between sites and countries in Russia and the CIS, allowing for future comparative analysis of results.

However, there are limitations in the data obtained from disease registries that must be considered. First, diagnostic criteria, treatment evaluation, and outcomes may differ. Data are generally not validated, so there may be a lack of complete data and follow-up information for all patients. In addition, there may be limitations in the use of the resulting evidence-for example, the infrastructure for healthcare technology assessment in Russia and the CIS is still evolving, and analytic data informing optimal patient movement and diagnosis may not always be available under budget constraints.

At the end of the discussion, participants agreed that pharmaceutical companies have an increasingly important role to play in raising awareness of disease situations, understanding patient care processes, and identifying unmet needs. Evidence from local clinical practice, as well as similar disease registries developed for patients with Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and IBD, will help inform new decisions for providers, as well as improve disease diagnosis, access to innovative treatments,f and patient outcomes in Russia-CIS.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Corrections to clinical trial documents due to COVID-19. Russian experience.
Read More
Publications
WHAT IS BIOEQUIVALENCE
Read More
Publications
THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

2 + 2 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Guidelines for amending clinical trial documents due to COVID. Russian Expe... Ensuring continuity of Pharmacovigilance activities in a COVID pandemic
Scroll to top